Semaglutide Trials Near Me: What the Research Found and What Comes Next

What the completed semaglutide trials actually showed

The STEP programme (a series of large phase 3 trials) is the evidence base behind Wegovy's UK licence. STEP 1 randomised 1,961 adults with obesity or overweight and at least one weight-related condition (but without type 2 diabetes) to either semaglutide 2.4mg once weekly or placebo, alongside lifestyle support, for 68 weeks. The result: an average body-weight reduction of around 15% in the semaglutide group, compared with roughly 2.4% in the placebo group. That data, published in the New England Journal of Medicine, formed the backbone of NICE's appraisal and the MHRA licensing decision. STEP 2 focused on adults with type 2 diabetes; STEP 3 added an intensive behavioural intervention; STEP 4 looked at what happens when treatment stops. Across the programme, the consistent finding was that semaglutide produced meaningful, sustained weight loss when paired with diet and activity changes, and that much of the weight returned when the medicine was discontinued. Semaglutide is a GLP-1 receptor agonist: it works partly by slowing how quickly food leaves the stomach and partly by acting on brain regions that govern appetite, so you feel full on less. The research is settled enough that regulators acted on it. If you're curious about finding a Wegovy trial near you, it's worth understanding that searching for an active trial is no longer the route most people need to take.

Why 'trial near me' searches often reflect a gap between NHS access and private access

When people search for semaglutide trials near them, they're often hoping to access the medicine at reduced or no cost while NHS waiting lists stretch on. That's an understandable instinct. NHS access to Wegovy is tied to NICE guidance (TA875), which limits it to specialist weight management services with multidisciplinary support, for a maximum of two years, and demand has far outpaced capacity in many areas. Some people also look to trials because they've heard about newer doses or formulations still in development and want to be among the first to try them. Both motivations make sense. But it's worth being clear about what a clinical trial actually involves: randomisation (you may receive a placebo), strict eligibility criteria, frequent monitoring visits, and the possibility of being withdrawn if your health picture changes. Participation is a genuine research commitment, not simply early or cheaper access. For most people who qualify medically, a private prescription through a regulated pharmacy is simpler, faster and more predictable. You can read more about finding semaglutide near you through licensed routes if you want a clearer sense of the practical options. The cost of private treatment varies by dose and provider, a realistic overview of what's involved financially is on our Wegovy cost page.

How to find legitimate ongoing semaglutide research in the UK

If your reason for searching is genuine interest in participating in research (contributing to the evidence base, or accessing an investigational dose) there are legitimate routes. The UK Clinical Trials Gateway and the NIHR's Be Part of Research database list registered studies recruiting in the UK, searchable by condition and location. Novo Nordisk, the manufacturer of Wegovy, also lists active studies on its website. Any legitimate trial will be registered on a public database, approved by a Research Ethics Committee, and will not charge you to participate. The treating team will explain exactly what you'd receive, what the monitoring schedule looks like, and what happens at the end of the study period. If you're approached via social media or an unsolicited email about a 'semaglutide trial' that asks for payment or promises guaranteed access to the medicine, treat it as a serious red flag. You may also have seen references to rebellious semaglutide, a term that has circulated online in connection with unregulated sources, and it is precisely that kind of offer that the MHRA's Yellow Card scheme exists to help you report. The MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk lets you report suspected counterfeit products or illegal sellers. For most people, the more practical path is simply a consultation with a prescriber who can assess whether semaglutide is right for them now, based on completed trial evidence and your own health picture.

What eligibility for semaglutide looks like outside a trial setting

The licensed criteria for Wegovy in the UK are based on the same population studied in the STEP trials: adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, prediabetes or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds, in line with NICE's appraisal of semaglutide (TA875). A BMI figure alone doesn't decide things, the prescriber looks at your full health picture, any medicines you take, and whether there are reasons semaglutide might not be appropriate. At nume, every consultation is read and assessed by a GPhC-registered Independent Prescriber on the same day it's submitted; your answers land on a clinician's desk, not in an automated queue. The pen itself is delivered by DPD the next working day in plain packaging, the kind of thing you can keep in the fridge door without it being anyone else's business. Our clinical team oversees the pharmacy's prescribing standards, and you can read more about how the service works on our about us page. If you'd like to understand the broader landscape of licensed weight-loss treatments, the weight-loss treatments overview sets out the options clearly.